Financial burden of COVID-19 for a hospital-type medical organization
OBJECTIVES. To assess the structure of spending the financial resources of hospital for the purchase of medicines for the treatment of patients with COVID-19 on North-Western State Medical University. I.I. Mechnikov for the period of reprofiling during 2020-2021. Also to conduct a comparative analysis with the costs of treating patients who received treatment in non-reprofiled units. Materials and methods. With the help of ABC/VEN and ATC/DDD analyzes, the consumption of drugs used to treat patients with COVID-19, as well as for non-repurposed units, was estimated. Results. An analysis was made of the consumption of medicines in a medical organization during the period of re-profiling a part of the bed fund for the treatment of patients with COVID-19 in 2020-2021. Based on the results of the assessment of the structure of drug consumption, a significant excess in drug supply (for various pharmacological subgroups) of patients with COVID-19 was revealed in comparison with patients who received treatment in non-reprofiled units. Conclusion. Treatment of patients with COVID-19, subject to the methodological recommendations of the Ministry of Health for the diagnosis and treatment of a new coronavirus infection, is quite financially burdensome for a hospital. Given the shortage of drugs on the market in the conditions of the whole country at the beginning of the COVID-19 pandemic, some purchased drugs were almost completely used to treat patients of the Covid Center.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF